RAPIDe-3 In partnership with about 75 other institutions across the globe, the practice of Dr. Raffi Tachdjian is currently participating in the RAPIDe-3 study on hereditary angioedema (HAE) type 1 and type 2. The purpose of this study is to evaluate the efficacy and safety of an oral investigational drug,…
Sponsored Content
Recent Posts
- 1 lonvo-z dose keeps most HAE patients attack-free up to 3 years
- For many of us, becoming a patient advocate wasn’t optional
- FDA extends Orladeyo approval to children as young as 2
- With chronic illness, we can’t brush off holiday stress so easily
- Abrupt danazol stop in HAE can cause temporary hepatitis: Study